CCMB study points to new way of tackling fungal infections
You don’t have any Active Subscription.
Account subscription benefits alongside Premium Stories, Editorials, Opinions and more. Unlock these with Subscription
Scientists at the CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, have identified a promising new strategy to combat fungal infections by preventing disease-causing fungi from becoming invasive, rather than killing them outright.
Most current antifungal drugs work by destroying fungal cells. However, fungi can gradually develop resistance to these medicines, making infections increasingly difficult to treat. A team led by Sriram Varahan at CCMB studied ‘Candida albicans’, a fungus commonly found on human skin and in the body. While generally harmless, it can cause serious infections when it enters the bloodstream or internal organs.
The researchers focused on ‘morphogenesis’, in which the fungus changes from a round-cell form into long, filament-like structures, a transformation allowing the pathogen to evade the body’s immune defences and spread more effectively within tissues.
Earlier studies had shown that glycolysis, the process through which cells metabolise sugar, plays a key role in controlling this shape change. Building on these findings, the team screened a library of small molecules that target glycolysis and identified two compounds capable of blocking the transformation.
Although the fungus continued to grow, it remained in its harmless rounded form suggesting that the compounds could serve as “anti-infective” agents that reduce the fungus’ ability to cause disease without necessarily eliminating it.
The study also identified pyruvate kinase, an enzyme involved in sugar metabolism, as a crucial regulator of fungal morphogenesis. Researchers further found that one of the compounds reduced biofilm formation, a protective layer that helps fungi resist treatment. The compound also increased the effectiveness of widely used antifungal drugs such as fluconazole and amphotericin B.
In a mouse model of systemic Candida infection, treatment with the lead compound significantly improved survival rates, highlighting its potential for future therapeutic development. “Our findings suggest that fungal disease-associated behaviour can be targeted without necessarily stopping fungal growth,” said Dhrumi Shah, first author of the study. “We need further studies to evaluate the compounds effectiveness and safety but by blocking the fungus from becoming invasive, they could complement existing treatments,” said Sriram Varahan.
The findings, published in ACS Infectious Diseases, emerged from a collaboration between CSIR-CCMB and the BRIC-Translational Health Science and Technology Institute, said a press release on Tuesday.
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.